Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Chromatics Color Sciences International. Inc; CCSI -- Ignore unavailable to you. Want to Upgrade?

To: poodle who wrote (609)	12/16/1997 11:48:00 PM
From: poodle	Read Replies (1) \| Respond to of 5736

To all: sorry, but all tables looked good during editing. On the post they are completely unreadable. You may make your own. Some lines are shorter than they should be. For example, you will see 5X2.2=33. As you can imagine, it's 15, "1" somehow dissapeared. Too late to repair. Sorry.

To: poodle who wrote (609)	12/17/1997 1:12:00 AM
From: Quad Sevens	Read Replies (2) \| Respond to of 5736

"On average, it required 5.7 (range, 4.6 to 6.5) minutes of a phlebotomist's time to obtain a capillary blood sample for a serum bilirubin determination, whereas a TcB measurement required 27 (range, 10 to 40) seconds. The direct cost of performing a serum bilirubin determination was $2.20 per test, compared with $0.15 per test for a TcB measurement, a savings of $2.05 per test." The direct cost of $2.20 obviously does not include the labor of the phlebotomist, which is likely to be way over $2.20 for about 6 minutes of highly specialized (and well compensated) work. Note that CCSI's procedure decreases the amount of labor involved by a factor of 12 to 13; that should amount to substantial savings. "They do not include spectrofotometer price." Nor did they include the price of the lab equipment used for the standard test. "They did not calculate the price of education." For either procedure. "Remember that the simplest way to determine jaundice is still eye, almost 0 direct cost." Find a doctor out there who would use the eyeball test when CCSI's procedure is available and I'll show you a long line of lawyers. Wade

To: poodle who wrote (609)	12/17/1997 9:02:00 AM
From: JanyBlueEyes	Read Replies (1) \| Respond to of 5736

At 11:29PM Dec 16 poodle posted reply #609 on this board (CCSI) "What's with Arthur Guiry filing to sell 30,000 shares on December 4?" ....... --------------- At 11:37PM Dec 16 poodle posted this message on the Roger's 1997 Short Picks board: To all: Chromatics Color Sciences International Inc. (NASDAQ:CCSI) CEO is recomending to be patient and wait for the global agreement. Insiders are selling (last in Dec). Market size seems to be extremely overestimated. INVESTOR FACT SHEET looks very interesting(to me). If you are inerested in biology or medicine, you may like it. ------------ Gosh, do ya think he might have an agenda here???????????????????

To: poodle who wrote (609)	12/17/1997 4:14:00 PM
From: JanyBlueEyes	Read Replies (2) \| Respond to of 5736

I didn't want to have to do this *1. Great overestimation of the potential market size. (more than 10X in my calculations; I could b completely wrong)* From exchange2000.com - Comments on Size Of Market- listed on the CCSI Research Page: Existing market of bilirubin infant jaundice testing is $1.072 billion per year based on $330 million in the U.S., equivalent sized markets in each of Europe and China/Japan and about 1/4 that size in the rest of the Americas. This figure was determined by the number of tests performed. Please note, that is not the potential market for Colormate. The demand for the disposables would have some relationship to this number as they are consumed on a per test basis. But potential demand for the equipment itself would actually be based on the number of physical locations where the tests are performed. That figure was not given. from exchange2000.com - Comments on Size Of Market- listed on the CCSI Research Page: On the investor side, it seems as though many people are getting carried away with the discussion of the market size. I am also surprised that anyone can really announce a TAM (Total Available Market) with 4 significant figures! There is a touch of naivity. TAM is the largest possible market size covering all continents. A subset of TAM is called SAM (Servable Available Market), the portion of TAM that your company can conceivably and realistically serve. But in reality, a company should be very happy if they can meet 10-20% of the SAM. In laymen's term, market size, however you want to define it, is only the size of the pie on the dinner table. There is no telling who gets invited to dinner, no telling what your portion should be. To think that a 24-person (and growing) organization can capitalize a $1 billion market, is to believe that Liechtenstein can become a notable world power. They probably come close, but not within a few years. There are plenty of stumbling blocks to overcome (staffing to address each of the market, production logistics, quality of product over extended use, potential litigation as people blaming on the instrument for misdiagnosing, etc.) I support Darby, in her decision to grow slowly but surely. I would suggest that investors tuck away your shares and forget them for awhile. Let Darby go to work, instead of catering after you. This CCSI thing has the blockbuster potential, but it takes time. From exchange2000.com - CONFERENCE CALL TRANSCRIPT 9/17/97 - listed on the CCSI Research Page: Regarding pricing of CCSI's medical device, the Company is not able at this time to disclose the pricing structure and business models currently being discussed with the different potential distribution partners, including any increased market potential for non-invasive testing. When business discussions are completed with potential partners and/or licensees, the business models and pricing structure for the Company's medical system will be made available, along with the key terms and features of the Company's and its partners' 3-4 year business plan to achieve global market penetration, including distribution performance requirements. *2. Insiders selling.* This topic has been discussed.....and discussed.....and discussed.....and discussed..... *3. Luck of any agreement 6 mos after FDA approval.* exchange2000.com - Comments - listed on the CCSI Research Page: CCSI has received over the past several months, many proposals from a number of well known international companies. Recently CCSI received several more proposals which appear to be even MORE attractive to CCSI and its shareholders................... ........From what I understand, there are no "snags" or other difficulties; quite to the contrary, the company is in the enviable position of being presented with a significant number of attractive proposals from well known companies who want CCSI's technology and/or its applications. The CEO is interested in maximizing CCSI's value, and will take whatever time she feels she needs to complete that review. She is quite aware of the "interest" of CCSI shareholders in getting immediate "news", however, she believes that they will appreciate the effort she is making in maximizing their shareholder interest by not taking the first offer. *4. Luck of any market penetration for previous 9 years in any field.* See exchange2000.com - Timeline of how long it took for CCSI to conduct clinicals and submit to FDA - listed on the CCSI Research Page *5. Possibly incorrect direction: laptop type instead of hand-held simple devices.* Hand-held device will be marketed to other than medical industries. *6. Competition.* See exchange2000.com - CCSI Research Page (Look under "COMPETITION")

To: poodle who wrote (609)	12/17/1997 5:04:00 PM
From: Clayleas	Respond to of 5736

Poodle, <. How many per hospital we need? Well, 1 mashine per 11 infant does not looks like underestimations at all. 5,000 mashines should be requered.> I'm not sure why you assume only one unit per hospital is all CCSI will sell. Do you think there might be a need for units in emergency rooms? How about in pediatricians' offices? Oh yes, and with all of the managed care now days, do you think some borderline infants might be released from the hospital earlier if they can be sent home with a unit like now happens with infant monitors? And with those home units being used by nervous new parents, you might even see those very profitable disposables being used at maybe 3 times the recommended rate. To top it all off, you haven't even addressed the dental, cosmetic, decorating, and industrial uses. So be my guest and short the stock and go ahead and convince as many others as you can. But please, don't close your position until after you hear the news in the first few months of 1998. Jim